Article Data

  • Views 685
  • Dowloads 149

Original Research

Open Access

Lorazepam attenuates neuroinflammation by suppressing T cell infiltration in diabetic peripheral neuropathy

  • Ying Wang1
  • Yaping Sui2
  • Chunli Xing1,*,

1Department of Geratology, People’s Hospital of Lixia District of Jinan, 250014 Jinan, Shandong, China

2Medical Record Management Division, Yantai Affiliated Hospital of Binzhou Medical University, 264100 Yantai, Shandong, China

DOI: 10.22514/sv.2024.113 Vol.20,Issue 9,September 2024 pp.72-78

Submitted: 28 April 2024 Accepted: 09 July 2024

Published: 08 September 2024

*Corresponding Author(s): Chunli Xing E-mail: chunli_dr@163.com

Abstract

Diabetic peripheral neuropathy (DPN) is a chronic microvascular complication of diabetes mellitus that results in significant pain and severely affects patients’ quality of life. In this context, lorazepam has demonstrated promising pharmacological effects, specifically through its antidepressant and antiepileptic properties, in the management of various diseases. However, the regulatory effects and pathways associated with lorazepam in the progression of DPN remain unclear. In this study, a DPN rat model was successfully established, and further investigations showed a reduction in the exit threshold (g) in DPN rats, which was reversed after lorazepam treatment, indicating that lorazepam can alleviate mechanical allodynia in DPN rats. Additionally, lorazepam treatment reduced inflammation in DPN rats. Furthermore, lorazepam inhibited T cell infiltration in the dorsal root ganglion (DRG) of DPN rats, and the activated nuclear factor kappa-B (NF-κB) and nuclear factor erythroid 2-related factor 2 (Nrf2) pathways in DPN rats were suppressed by lorazepam treatment. In conclusion, lorazepam reduced neuroinflammation by inhibiting T cell infiltration, thereby ameliorating DPN. These findings may provide novel insights into the therapeutic potential of lorazepam for the treatment of DPN.


Keywords

Lorazepam; Neuroinflammation; T cell infiltration; Diabetic peripheral neuropathy


Cite and Share

Ying Wang,Yaping Sui,Chunli Xing. Lorazepam attenuates neuroinflammation by suppressing T cell infiltration in diabetic peripheral neuropathy. Signa Vitae. 2024. 20(9);72-78.

References

[1] Cloete L. Diabetes mellitus: an overview of the types, symptoms, complications and management. Nursing Standard. 2022; 37: 61–66.

[2] Røikjer J, Ejskjaer N. Diabetic peripheral neuropathy. Handbook of Experimental Pharmacology. 2022; 274: 309–328.

[3] Jang HN, Oh TJ. Pharmacological and nonpharmacological treatments for painful diabetic peripheral neuropathy. Diabetes & Metabolism Journal. 2023; 47: 743–756.

[4] Boulton AJM, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et al. Diabetic neuropathies: a statement by the American diabetes association. Diabetes Care. 2005; 28: 956–962.

[5] Xiang Y, Dai J, Xu L, Li X, Jiang J, Xu J. Research progress in immune microenvironment regulation of muscle atrophy induced by peripheral nerve injury. Life Sciences. 2021; 287: 120117.

[6] Hirjak D, Fricchione G, Wolf RC, Northoff G. Lorazepam in catatonia—Past, present and future of a clinical success story. Schizophrenia Research. 2024; 263: 27–34.

[7] Ameer B, Greenblatt DJ. Lorazepam: a review of its clinical pharmacological properties and therapeutic uses. Drugs. 1981; 21: 162–200.

[8] Hung YY, Huang TL. Lorazepam and diazepam rapidly relieve catatonic features in major depression. Clinical Neuropharmacology. 2006; 29: 144–147.

[9] Patterson DR, Ptacek TJ, Carrougher GJ, Sharar SR. Lorazepam as an adjunct to opioid analgesics in the treatment of burn pain. Pain. 1997; 72: 367–374.

[10] Stude P, Lenz M, Höffken O, Tegenthoff M, Dinse H. A single dose of lorazepam reduces paired-pulse suppression of median nerve evoked somatosensory evoked potentials. European Journal of Neuroscience. 2016; 43: 1156–1160.

[11] Vogel LR, Muskin PR, Collins ED, Sloan RP. Lorazepam reduces cardiac vagal modulation in normal subjects. Journal of Clinical Psychopharmacology. 1996; 16: 449–453.

[12] Cornwell AC, Tisdale AA, Venkat S, Maraszek KE, Alahmari AA, George A, et al. Lorazepam stimulates IL6 production and is associated with poor survival outcomes in pancreatic cancer. Clinical Cancer Research. 2023; 29: 3793–3812.

[13] Covelli V, Maffione AB, Greco B, Cannuscio B, Calvello R, Jirillo E. In vivo effects of alprazolam and lorazepam on the immune response in patients with migraine without aura. Immunopharmacology and Immunotoxicology. 1993; 15: 415–428.

[14] Boerth JA, Chinn AJ, Schimpl M, Bommakanti G, Chan C, Code EL, et al. Discovery of a novel benzodiazepine series of Cbl-b inhibitors for the enhancement of antitumor immunity. ACS Medicinal Chemistry Letters. 2023; 14: 1848–1856.

[15] Cheng Y, Chen Y, Li K, Liu S, Pang C, Gao L, et al. How inflammation dictates diabetic peripheral neuropathy: an enlightening review. CNS Neuroscience & Therapeutics. 2024; 30: e14477.

[16] Tang HY, Wang FJ, Ma JL, Wang H, Shen GM, Jiang AJ. Acupuncture attenuates the development of diabetic peripheral neuralgia by regulating P2X4 expression and inflammation in rat spinal microglia. The Journal of Physiological Sciences. 2020; 70: 45.

[17] Chen J, Guo P, Liu X, Liao H, Chen K, Wang Y, et al. Sinomenine alleviates diabetic peripheral neuropathic pain through inhibition of the inositol-requiring enzyme 1 alpha-X-box binding protein 1 pathway by downregulating prostaglandin-endoperoxide synthase 2. Journal of Diabetes Investigation. 2023; 14: 364–375.

[18] Li Y, Zhang Y, Liu DB, Liu HY, Hou WG, Dong YS. Curcumin attenuates diabetic neuropathic pain by downregulating TNF-α in a rat model. International Journal of Medical Sciences. 2013; 10: 377–381.

[19] Wang Y, Sadike D, Huang B, Li P, Wu Q, Jiang N, et al. Regulatory T cells alleviate myelin loss and cognitive dysfunction by regulating neuroinflammation and microglial pyroptosis via TLR4/MyD88/NF-κB pathway in LPC-induced demyelination. Journal of Neuroinflammation. 2023; 20: 41.

[20] Zeng J, Liao Z, Yang H, Wang Q, Wu Z, Hua F, Zhou Z. T cell infiltration mediates neurodegeneration and cognitive decline in Alzheimer’s disease. Neurobiology of Disease. 2024; 193: 106461.

[21] González H, Pacheco R. T-cell-mediated regulation of neuroinflammation involved in neurodegenerative diseases. Journal of Neuroinflammation. 2014; 11: 201.

[22] Laurent C, Dorothée G, Hunot S, Martin E, Monnet Y, Duchamp M, et al. Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy. Brain. 2017; 140: 184–200.

[23] Hong H, Lou S, Zheng F, Gao H, Wang N, Tian S, et al. Hydnocarpin D attenuates lipopolysaccharide-induced acute lung injury via MAPK/NF-κB and Keap1/Nrf2/HO-1 pathway. Phytomedicine. 2022; 101: 154143.

[24] Li C, Liu M, Deng L, Luo D, Ma R, Lu Q. Oxyberberine ameliorates TNBS-induced colitis in rats through suppressing inflammation and oxidative stress via Keap1/Nrf2/NF-κB signaling pathways. Phytomedicine. 2023; 116: 154899.

[25] Li CL, Liu XH, Qiao Y, Ning LN, Li WJ, Sun YS, et al. Allicin alleviates inflammation of diabetic macroangiopathy via the Nrf2 and NF-kB pathway. European Journal of Pharmacology. 2020; 876: 173052.

[26] Mansouri A, Reiner Ž, Ruscica M, Tedeschi-Reiner E, Radbakhsh S, Bagheri Ekta M, et al. Antioxidant effects of statins by modulating Nrf2 And Nrf2/Ho-1 signaling in different diseases. Journal of Clinical Medicine. 2022; 11: 1313.

[27] Tseng KF, Tsai PH, Wang JS, Chen FY, Shen MY. Sesamol attenuates renal inflammation and arrests reactive-oxygen-species-mediated IL-1β secretion via the ho-1-induced inhibition of the IKKα/NFκB pathway in vivo and in vitro. Antioxidants. 2022; 11: 2461.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

Index Copernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus: CiteScore 1.3 (2023) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time

Conferences

Top